Predicting Successful Phase Advancement and Regulatory Approval in Multiple Myeloma From Phase I Overall Response Rates RCTs from two scenarios—upfront treatment of chronic myelogenous leukemia and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback